IceCure Medical Ltd (ICCM) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

IceCure Medical Ltd (ICCM) Healthcare & Pipeline Overview

IceCure Medical Ltd. focuses on cryoablation technology, offering the ProSense system for tumor treatment. With a presence in the medical device sector, the company targets minimally invasive solutions, particularly in breast cancer, differentiating itself through innovative freezing technology for tumor destruction.

What Is the Investment Thesis for ICCM?

IceCure Medical presents a focused investment opportunity within the medical device sector, centered around its ProSense cryoablation system. The company's technology offers a minimally invasive alternative for tumor treatment, primarily targeting breast cancer. A key value driver is the potential for expanded applications of ProSense to other types of tumors, pending further clinical trials and regulatory approvals. Growth catalysts include increasing adoption of cryoablation as a preferred treatment method and strategic partnerships to broaden market access. However, the company's negative profit margin of -445.6% and a high beta of 2.52 indicate significant financial risk and market volatility. Successful commercialization and positive clinical outcomes are crucial for realizing the company's growth potential by 2028.

Based on FMP financials and quantitative analysis

ICCM Key Highlights

Market capitalization of $5.52M reflects its small-cap status within the medical device industry.

• Gross margin of 36.3% indicates the profitability of its ProSense system before operating expenses.
• Negative profit margin of -445.6% highlights significant challenges in achieving overall profitability.
• Beta of 2.52 suggests high volatility compared to the broader market, indicating higher investment risk.
• Focus on cryoablation technology provides a niche market position in minimally invasive tumor treatment.

Who Are ICCM's Competitors?

ICCM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ICCM's Key Strengths?

Proprietary cryoablation technology.

• Minimally invasive treatment approach.
• Focus on breast tumor treatment.
• Established presence in key markets.

What Are ICCM's Weaknesses?

Negative profit margin.

• High beta indicating volatility.
• Limited product portfolio.
• Small market capitalization.

What Could Drive ICCM Stock Higher?

ICCM catalyst: Publication of clinical trial results demonstrating the efficacy of ProSense for new tumor types (expected by Q4 2026).

• Regulatory approvals for expanded indications in key markets (anticipated by H1 2027).
• Increasing adoption of cryoablation as a preferred treatment method.
• Strategic partnerships to expand market reach and distribution.

What Are the Key Risks for ICCM?

Financial-distress signal — its Altman Z-Score of -11.76 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Competition from established medical device companies with greater resources.
• Regulatory hurdles and delays in obtaining approvals for new indications.
• Technological obsolescence and the emergence of alternative treatment methods.
• Negative profit margin and the need to raise additional capital.
• Market volatility and economic downturn affecting healthcare spending.

What Are the Growth Opportunities for ICCM?

• Expansion into New Therapeutic Areas: IceCure has the opportunity to expand the application of its ProSense system beyond breast tumors to other types of solid tumors, such as kidney and lung tumors. The global market for cancer therapies is projected to reach $200 billion by 2027. Successful clinical trials and regulatory approvals for new indications could significantly increase the company's addressable market. This expansion is expected to contribute to revenue growth starting in 2027.
• Geographic Market Expansion: IceCure can pursue growth by expanding its commercial presence into new geographic markets, particularly in Asia and Europe. The increasing prevalence of cancer and the growing demand for minimally invasive procedures in these regions present significant opportunities. Establishing strategic partnerships with local distributors and healthcare providers will be crucial for successful market entry. This expansion is anticipated to begin in 2026, with initial market penetration efforts.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger medical device companies or pharmaceutical companies can provide IceCure with access to broader distribution networks and increased marketing resources. Collaborations with research institutions can accelerate the development of new applications for its cryoablation technology. These partnerships are expected to materialize by 2027, enhancing the company's market reach and innovation capabilities.
• Increased Adoption of Cryoablation: As awareness of the benefits of cryoablation as a minimally invasive treatment option grows, IceCure can capitalize on the increasing adoption of this technology. Educating healthcare professionals and patients about the advantages of the ProSense system, such as reduced recovery time and fewer complications, will be essential. This ongoing effort is expected to drive incremental sales growth over the next several years.
• Development of Next-Generation Cryoablation Technology: Investing in the development of next-generation cryoablation technology can provide IceCure with a competitive edge and allow it to address a wider range of clinical needs. This includes improving the precision and efficiency of the ProSense system, as well as developing new cryoablation devices for different types of tumors. These technological advancements are expected to be introduced by 2028, further solidifying the company's market position.

What Are ICCM's Competitive Advantages?

• Proprietary cryoablation technology.
• Patents protecting the ProSense system.
• Clinical data supporting the efficacy of cryoablation.
• Established relationships with key opinion leaders in oncology.

What Does ICCM Do?

IceCure Medical Ltd., founded in 2006 and headquartered in Caesarea, Israel, is a medical device company dedicated to the research, development, and commercialization of cryoablation technologies. The company's flagship product, the ProSense system, offers a minimally invasive solution for the cryoablation (freezing) of tumors. Primarily, ProSense is used in the treatment of breast tumors, providing an alternative to traditional surgical methods. IceCure's technology aims to improve patient outcomes by offering a less invasive procedure that reduces recovery time and potential complications. The company's focus is on expanding the applications of its cryoablation technology to treat various types of tumors, solidifying its position in the medical device market. IceCure continues to innovate in the field of cryoablation, seeking regulatory approvals and partnerships to broaden the reach of its ProSense system and enhance its market presence. With a team of 64 employees, IceCure is committed to advancing cryoablation technology and making it a standard treatment option for tumor management.

What Products and Services Does ICCM Offer?

• Develops and commercializes cryoablation medical devices.
• Offers the ProSense system for freezing and destroying tumors.
• Focuses on minimally invasive treatment solutions.
• Targets breast tumors as a primary application.
• Conducts research to expand applications of cryoablation.
• Seeks regulatory approvals for its medical devices.
• Provides an alternative to traditional surgical methods.

How Does ICCM Make Money?

• Sells the ProSense system to hospitals and clinics.
• Generates revenue from the sale of disposable cryoprobes.
• Provides training and support services to healthcare providers.
• Pursues strategic partnerships for distribution and marketing.

What Industry Does ICCM Operate In?

IceCure Medical operates within the medical device industry, specifically in the market for minimally invasive tumor ablation technologies. The global medical device market is projected to reach $600 billion by 2028, driven by technological advancements and an aging population. The competitive landscape includes established players offering alternative ablation methods such as radiofrequency ablation and microwave ablation. IceCure differentiates itself through its cryoablation technology, which offers unique advantages in certain applications. The company's success depends on its ability to demonstrate the clinical efficacy and cost-effectiveness of its ProSense system compared to existing treatments.

Who Are ICCM's Key Customers?

• Hospitals and medical centers.
• Oncology clinics.
• Breast cancer treatment centers.
• Radiology centers.

Company Profile

IceCure Medical Ltd operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Caesarea, IL. The company is led by CEO Eyal Shamir. ICCM has traded publicly since 2021.

IceCure Medical Ltd's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -11.76 places it in the distress zone, a signal of elevated financial risk.

ICCM Valuation & Market Position

With a $5.52M market cap, IceCure Medical Ltd sits in the micro-cap segment of the market. Relative to its peer group, ICCM's quantitative score of 55/100 is below the peer average of 70/100.

Quarterly Financial Performance: IceCure Medical Ltd

Revenue for IceCure Medical Ltd came in at $907K during Q2 2026. The company recorded a net loss of $4.5M, with diluted EPS of $-1.46. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, ICCM averaged $-1.69 in diluted EPS.

IceCure Medical Ltd has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 21.2% below estimates on average.

Wall Street analysts project IceCure Medical Ltd revenue of about $6.4M for fiscal 2026, with EPS near $-5.67.

ICCM Financials

ICCM Latest News

ICCM Analyst Consensus

ICCM MoonshotScore

Common Questions About ICCM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources